Skip to main content

ANALISIS EPIGENOMICO INTEGRAL DEL LINFOMA PLASMABLÁSTICO: IDENTIFICACION DE CARACTERISTICAS EPIGENETICAS PARA MEJORAR EL DIAGNOSTICO Y PRONOSTICO DE LOS PACIENTES

PI19/01588

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION CONTRA LA LEUCEMIA JOSEP CARRERAS
Execution centre FUNDACION INSTITUTO DE INVESTIGACION CONTRA LA LEUCEMIA JOSEP CARRERAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential

  • Verdú-Bou, Miriam|||0000-0003-4062-0549
  • Baptista, Maria Joao|||0000-0003-3471-2535
  • Ribeiro, ML
  • Méndez-López, Aleix
  • Profitós-Pelejà, Núria|||0000-0001-8923-6025
  • Frontzek, Fabian|||0000-0003-1705-3638
  • Roué, Gaël|||0000-0003-0245-2257
  • Mate, José Luís
  • Pellicer, Mireia
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Castellvi, Josep|||0000-0001-5745-9996
  • Bastos, Mariana|||0000-0002-9431-4646
  • Menárguez, Javier
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • González Barca, Eva|||0000-0002-1323-1508
  • Climent, Fina|||0000-0002-4360-8388
  • Salar Silvestre, Antonio|||0000-0002-4652-4825
  • Sancho, Juan-Manuel|||0000-0001-7168-6538
  • Staiger, Annette M.|||0000-0002-5896-3200
  • Ott, German|||0000-0001-7990-6793
  • Anagnostopoulos, Ioannis
  • Esteller, M.|||0000-0003-4490-6093
  • Lenz, Georg|||0000-0002-4728-1693
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Navarro Ferrando, José Tomás|||0000-0001-9101-6013
Plasmablastic lymphoma (PBL) is an uncommon and aggressive B-cell lymphoma with a poor prognosis. Some studies have described genetic alterations in PBL, but its transcriptome has been scarcely studied, and molecular mechanisms driving lymphomagenesis remain poorly understood. Our goal was to delineate transcriptomic profiles to identify potential biomarkers for novel targeted therapy in PBL. RNA sequencing uncovered an enrichment of cell cycle-related genes, including MYC and E2F targets, and genes involved in G2/M checkpoint in PBL. Microarray analyses discovered 2 microRNA expression signatures depending on the presence of MYC translocation. Interestingly, miR-150-5p was downregulated, whereas E2F3 and BIRC5 (survivin), a cell cycle activator and an antiapoptotic regulator, respectively, were upregulated. Increasing miR-150-5p in PBL-1 cells induced G1 cell cycle arrest, suppressed proliferation by transcriptionally repressing E2F3, and promoted apoptosis by the downregulation of BIRC5. Interestingly, the miR-150-5p tumor suppressor activity was diminished in E2F3 -knockdown cells. The combined inhibition of E2F3 and survivin attenuated lymphomagenesis in PBL cells and suppressed tumor growth in a chorioallantoic membrane-derived xenograft model of PBL. Overall, our study highlights the pivotal role of the miR-150-5p/E2F3/survivin axis in boosting PBL lymphomagenesis and unveils new therapeutic targets for this lymphoma.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population, diagnostic and prognostic implications

  • Baptista, Maria Joao|||0000-0003-3471-2535
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Muñoz-Marmol, Ana Maria
  • Muncunill Farreny, Josep|||0000-0002-7678-0205
  • García, Olga
  • Montoto, Silvia|||0000-0002-3006-9725
  • Gribben, John G.
  • Calaminici, Maria
  • Martinez, Antonio
  • Veloza, Luis
  • Martínez-Trillos, Alejandra
  • Aldámiz-Echevarría Lois, Maria Teresa|||0000-0002-4374-6940
  • Menarguez, Javier
  • Terol, Maria José
  • Ferrandez, Antonio
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Briones Meijide, Javier|||0000-0003-2750-3735
  • González Barca, Eva|||0000-0002-1323-1508
  • Climent, Fina|||0000-0002-4360-8388
  • Muntañola, Ana|||0000-0001-7839-6648
  • Moraleda, José María|||0000-0001-9080-1466
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Abella Monreal, Eugenia|||0000-0001-9605-8458
  • Colomo, Luis|||0000-0001-5236-5085
  • García-Ballesteros, Carlos
  • Garcia-Caro, Montserrat
  • Sancho, Juan-Manuel|||0000-0001-7168-6538
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Mate Sanz, Jose Luís|||0000-0002-4829-3426
  • Navarro Ferrando, José Tomás|||0000-0001-9101-6013
The frequency of aggressive subtypes of B-cell non-Hodgkin lymphoma (B-NHL), such as high-grade B-cell lymphomas (HGBL) with MYC and BCL2 and/or BCL6 rearrangement (HGBL-DH/TH) or Burkitt-like lymphoma (BL) with 11q aberration, is not well known in the HIV setting. We aimed to characterise HIV-associated aggressive B-NHL according to the 2017 WHO criteria, and to identify genotypic and phenotypic features with prognostic impact. Seventy-five HIV-associated aggressive B-NHL were studied by immunohistochemistry (CD10, BCL2, BCL6, MUM1, MYC, and CD30), EBV-encoded RNAs (EBERs), and fluorescence in situ hybridisation (FISH) to evaluate the status of the MYC, BCL2, and BCL6 genes and chromosome 11q. The 2017 WHO classification criteria and the Hans algorithm, for the cell-of-origin classification of diffuse large B-cell lymphomas (DLBCL), were applied. In DLBCL cases, the frequencies of MYC and BCL6 rearrangements (14.9 and 27.7%, respectively) were similar to those described in HIV-negative patients, but BCL2 rearrangements were infrequent (4.3%). MYC expression was identified in 23.4% of DLBCL cases, and coexpression of MYC and BCL2 in 13.0%, which was associated with a worse prognosis. As for BL cases, the expression of MUM1 (30.4%) conferred a worse prognosis. Finally, the prevalence of HGBL-DH/TH and BL-like with 11q aberration are reported in the HIV setting. The phenotypic and genotypic characteristics of HIV-associated aggressive B-NHL are similar to those of the general population, except for the low frequency of BCL2 rearrangements in DLBCL. MYC and BCL2 coexpression in DLBCL, and MUM-1 expression in BL, have a negative prognostic impact on HIV-infected individuals.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Hodgkin lymphoma in people living with hiv

  • Navarro Ferrando, José Tomás|||0000-0001-9101-6013
  • Moltó, José|||0000-0003-4564-1963
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Ribera, Jose-Maria|||0000-0003-1042-6024
Despite widespread use of combined antiretroviral therapy (cART) and increased life expectancy in people living with HIV (PLWH), HIV-related lymphomas (HRL) remain a leading cause of cancer morbidity and mortality for PLWH, even in patients optimally treated with cART. While the incidence of aggressive forms of non-Hodgkin lymphoma decreased after the advent of cART, incidence of Hodgkin lymphoma (HL) has increased among PLWH in recent decades. The coinfection of Epstein-Barr virus plays a crucial role in the pathogenesis of HL in the HIV setting. Currently, PLWH with HRL, including HL, are treated similarly to HIV-negative patients and, importantly, the prognosis of HL in PLWH is approaching that of the general population. In this regard, effective cART during chemotherapy is strongly recommended since it has been shown to improve survival rates in all lymphoma subtypes, including HL. As a consequence, interdisciplinary collaboration between HIV specialists and hemato-oncologists for the management of potential drug-drug interactions and overlapping toxicities between antiretroviral and antineoplastic drugs is crucial for the optimal treatment of PLWH with HL. In this article the authors review and update the epidemiological, clinical and biological aspects of HL presenting in PLWH with special emphasis on advances in prognosis and the factors that have contributed to it.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical and therapeutic implications of epstein-barr virus in hiv-related lymphomas

  • Verdu-Bou, Miriam
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Hernandez-Rodriguez, Agueda|||0000-0002-0650-2680
  • Navarro Ferrando, José Tomás|||0000-0001-9101-6013
The incidence of lymphomas is increased in people living with HIV (PLWH). Aggressive B-cell non-Hodgkin lymphomas (NHLs) are the most common and are considered an AIDS-defining cancer (ADC). Although Hodgkin lymphoma (HL) is not considered an ADC, its incidence is also increased in PLWH. Among all HIV-related lymphomas (HRL), the prevalence of Epstein-Barr virus (EBV) is high. It has been shown that EBV is involved in different lymphomagenic mechanisms mediated by some of its proteins, contributing to the development of different lymphoma subtypes. Additionally, cooperation between both HIV and EBV can lead to the proliferation of aberrant B-cells, thereby being an additional lymphomagenic mechanism in EBV-associated HRL. Despite the close relationship between EBV and HRL, the impact of EBV on clinical aspects has not been extensively studied. These lymphomas are treated with the same therapeutic regimens as the general population in combination with cART. Nevertheless, new therapeutic strategies targeting EBV are promising for these lymphomas. In this article, the different types of HRL are extensively reviewed, focusing on the influence of EBV on the epidemiology, pathogenesis, clinical presentation, and pathological characteristics of each lymphoma subtype. Moreover, novel therapies targeting EBV and future strategies to treat HRL harboring EBV are discussed.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diffuse Large B-Cell Lymphoma in the HIV Setting

  • Huguet, María
  • Navarro Ferrando, José Tomás|||0000-0001-9101-6013
  • Moltó, José|||0000-0003-4564-1963
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Tapia, Gustavo|||0000-0003-1882-0368
Non-Hodgkin lymphoma (NHL) is one of the most frequent HIV-related neoplasms, and diffuse large B-cell lymphoma (DLBCL) is the most common subtype. In people with HIV (PWH), DLBCL classically presents with aggressive characteristics. As in the general population, HIV-related DLBCL is a heterogeneous disease that includes morphological and molecular subtypes. When combined antiretroviral therapy (cART) became widely available, a strong improvement of the immune function and a better management of infectious complications during lymphoma treatment were observed in PWH with lymphoma. Moreover, the concomitant treatment of cART with chemotherapy was shown to be beneficial. These changes have led to a marked improvement in prognosis for PWH with DLBCL, approaching that of the general population. Despite the widespread use of combined antiretroviral therapy (cART) and the subsequent decrease in AIDS-defining cancers, HIV-related lymphomas remain a leading cause of morbidity and mortality in people with HIV (PWH). Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL) subtype in PWH. This lymphoma is a heterogeneous disease including morphological variants and molecular subtypes according to the cell of origin or the mutation profile. In the pre-cART era, treatment with standard-dose chemotherapy induced high rates of toxicity and outcomes were very poor. The introduction of cART and the incorporation of infection prophylaxis allowed the use of conventional intensive chemotherapy regimens used in the general population, such as R-CHOP or R-EPOCH. The use of cART during chemotherapy treatment was initially controversial due to the potential risk of adverse drug-drug interactions. However, the availability of current cART regimens with less potential to cause drug interactions and evidence that cART improves survival rates in NHL strongly support the use of cART in PWH with DLBCL. Consequently, interdisciplinary collaboration between HIV specialists and hemato-oncologists for the management of potential interactions and overlapping toxicities between antiretroviral and antineoplastic drugs is crucial for the optimal treatment of PWH with NHL.